NEW YORK (GenomeWeb News) – Eurogentec said today that it has reached an agreement to acquire proteomics company AnaSpec for an undisclosed sum.
The agreement will give Eurogentec the potential to offer both genomics and proteomics tools for biotech, pharmaceutical, and diagnostics markets, the company said.
AnaSpec, based in Fremont, Calif., provides integrated proteomics solutions and specializes in peptide synthesis, labeled peptides and antibodies, fluorescent dyes, enzymatic activities, and assays for basic research, high-throughput screening, and drug discovery.
Eurogentec said it plans to maintain AnaSpec's facility and employees in Fremont, and that AnasSpec's co-founders, President Anita Hong and CEO Frank Hong, will remain with the company in leading roles.
Eurogentec CEO Jean-Pierre Delwart said in a statement that the deal "considerably strengthens Eurogentec's geographical presence in the US," and the company will market and support AnaSpec's products in Europe.
Financial terms of the agreement were not released.